Share this video  

ESMO 2023 | Novel treatment options for HER2-low breast cancer

Eva Ciruelos, MD, PhD, University Hospital October 12, Madrid, Spain, comments on the latest therapeutic modalities for HER2-low breast cancer. Trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, has shown very promising results in the Phase III DESTINY-Breast04 trial (NCT03734029). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.